Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis to Acquire Genomica

SAN FRANCISCO, Nov. 19 - Exelixis has agreed to acquire Genomica for a stock-for-stock transaction valued at $110 million, the companies announced on Monday.

 

The agreement, approved by both companies' board of directors, calls for South San Francisco, Calif.-based Exelixis to put in an offer for 100 percent of Genomica's outstanding common stock on or about Nov. 27, according to the companies. Following the stock buy, the companies expect to merge during the first quarter of 2002.

 

"We believe that Genomica's substantial cash and investments will significantly enhance our ability to move our drug discovery programs forward, and that their software will be an important tool to manage human data during the clinical development of our compounds," George Scangos, CEO of Exelixis, said in a statement.

 

Genomica's customers include AstraZeneca, GlaxoSmithKline, Aventis, and the National Cancer Institute. Genomica, based in Boulder, Colo., has alliances with Applied Biosystems and Celera Genomics, according to the company. As of Sept. 30, Genomica had $110.8 million in cash, cash equivalents, and investments.

 

Exelixis is a genomics-based drug discovery company with a research and development focus on comparative genomics and model genetic systems.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.